MBX (MBX Biosciences) Equity-to-Asset : 0.96 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MBX Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $257.44 Mil. MBX Biosciences's Total Assets for the quarter that ended in Dec. 2024 was $268.54 Mil.

The historical rank and industry rank for MBX Biosciences's Equity-to-Asset or its related term are showing as below:

MBX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.95 Med: -0.86 Max: 0.96
Current: 0.96

During the past 3 years, the highest Equity to Asset Ratio of MBX Biosciences was 0.96. The lowest was -0.95. And the median was -0.86.

MBX's Equity-to-Asset is ranked better than
97.08% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs MBX: 0.96

MBX Biosciences Equity-to-Asset Historical Data

The historical data trend for MBX Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Equity-to-Asset Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Equity-to-Asset

-0.95

-0.86

0.96

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial			-	-0.86	-1.56	0.96	0.96

Competitive Comparison of MBX Biosciences's Equity-to-Asset

For the Biotechnology subindustry, MBX Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

MBX Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

MBX Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	257.442	/	268.535
	=

MBX Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	257.442	/	268.535
	=

MBX Biosciences (NAS:MBX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

MBX Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.